Introduction: Higher target conformity and better sparing of organs at risk with modern radiotherapy (RT) may result in higher tumor control and less toxicity. In this study, we compare our institutional multimodality therapy experience of adjuvant chemotherapy and hemithoracic intensity-modulated pleural RT (IMPRINT) with previously used adjuvant conventional RT (CONV) in patients with malignant pleural mesothelioma (MPM) treated with lung-sparing pleurectomy/decortication (P/D).
Introduction
Malignant pleural mesothelioma (MPM) is a rare and aggressive malignancy affecting the pleura and commonly associated with previous asbestos exposure. Although some advances have been made in the various therapeutic approaches (including lung-sparing surgical technique, chemotherapy drug types and doses, and radiation therapy [RT] techniques), their impact on patient outcomes in a multimodality context remains unclear.
For patients with a favorable histological type and resectable disease, cytoreductive surgery with the goal of a macroscopically complete resection (MCR) has been the centerpiece of multimodality management at our institution. The debate about the optimal surgical procedure in MPM is ongoing. When compared retrospectively, patients undergoing lung-sparing techniques with complete resection (pleurectomy/decortication [P/D] and extended P/D [EPD]) as opposed to patients having an extrapleural pneumonectomy (EPP) were found to have at least equivalent overall survival (OS) with less postoperative morbidity and mortality than after EPP. [1] [2] [3] [4] [5] This observation has led to a shift in surgical approach from predominantly EPPs to more frequent use of lungsparing approaches such as P/D and EPD. To exclude confounding by surgical approach, this study includes only patients who underwent a lung-sparing operation. We used the International Association of the Study of Lung Cancer Mesothelioma Domain and the International Mesothelioma Interest Group definitions of P/D in this study. 6 Platinum/pemetrexed chemotherapy has been established as the standard of care for systemic therapy in patients with MPM because it was shown to significantly improve OS compared with platinum chemotherapy alone in a phase III trial (12.1 versus 9.3 months) (Vogelzang et al. 7 ), which was confirmed by a similar study using ralitrexed (van Meerbeeck et al.) 8 Typically, four cycles are administered in the setting of multimodality therapy delivered as either neoadjuvant or adjuvant therapy.
Adjuvant hemithoracic RT has been explored as part of multimodality treatment to reduce the risk of local and regional failure, especially after lung-sparing surgery, given the high risk of microscopic residual disease. Although two-dimensional combined photon/electron conventional RT (CONV) had historically been the standard technique available at the time, the development of intensity-modulated pleural RT (IMPRINT) in the past decade has made a more precise application of hemithoracic RT possible, reducing areas of dose uncertainty and doses to underlying organs at risk, in particular the lungs, but also the heart, liver, stomach, kidneys, and bowels. [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] In a recent prospective phase II trial we demonstrated the safety of hemithoracic IMPRINT after chemotherapy and P/D for patients with MPM. 19 In this study, we analyzed our institutional database to compare outcomes and toxicities of patients with MPM treated with a lung-sparing operation followed by either adjuvant CONV or IMPRINT.
Methods and Materials

Study Design and Patients
For this study, data on patients with MPM treated at our institution between 1974 and 2015 were collected from the institutional database. Patients were included if they had a lung-sparing operation as well as adjuvant RT.
Tumor information, treatment details, and follow-up data were retrieved from the patients' medical records. Toxicity was scored per the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0. Given the uncertainty about categorizing radiation pneumonitis, we defined grade 2 pneumonitis as requiring systemic treatment with prednisone and grade 3 pneumonitis as requiring treatment with continuous oxygen or hospitalization.
Treatment Characteristics
All patients underwent one of three lung-sparing types of surgical procedures, namely, EPD, P/D, or partial pleurectomy. Only 15 patients in the CONV group (11%) received chemotherapy, whereas 90% of patients in the IMPRINT group were treated with neoadjuvant or adjuvant chemotherapy. With the exception of two patients, all those in the IMPRINT group received a platinum/pemetrexed doublet.
The technique of CONV performed at our institution has been previously described by Kutcher et al. 20 and Gupta et al. 21 Patients were immobilized with their arms raised above their head in supine position. The field borders were the top of T1 superiorly, the bottom of L2/base of diaphragm inferiorly, the ribcage including the skin laterally, and the contralateral border of the vertebral bodies medially. A 1.5-to 2.0-cm margin was added medially if mediastinal nodes were involved. Patients were simulated by using fluoroscopy or computed tomography (CT), and the planning target volume was defined as the pleura and diaphragm with a 1-cm margin. Blocks were placed anteriorly and posteriorly over the abdomen and lung and (starting at 1980 cGy) over the heart in the case of left-sided tumors. There was a 15% scatter under the blocks from the photon fields; therefore, a supplemental daily electron dose of 153 cGy was prescribed. The spinal cord was excluded from the treatment field for the final two fractions to avoid overdosing.
RT was delivered in 180-cGy fractions with 6-MV photon beams by using linear accelerators.
Since 2004 we have developed a hemithoracic pleural intensity-modulated RT (IMRT) technique for patients with MPM that was previously described. 15, 16, 19 Patients were immobilized with their arms raised above their head in supine position. The initial planning target volume was defined by using the planning CT scan and encompassed the hemithoracic pleura and chest wall extending from the thoracic inlet to the insertion of the diaphragm at the L1-L2 vertebral body. A positron emission tomography/CT scan and respiratory correlated four-dimensional CT scan (available since 2008) were used to further refine the target volume. Radiation treatments were delivered in 180-cGy fractions with 6-MV photon beams by using Varian linear accelerators with a dynamic multileaf collimator (Varian Medical Systems, Palo Alto, CA).
Statistical Methods and Design
The primary end point of the analysis was OS; local failure (LF)-free survival and progression-free survival (PFS) were determined as well. All end points were measured from the start of RT until the date of event (death, LF, or progression, respectively) or until the last follow-up date. The Kaplan-Meier method was used for calculating OS rates, a Cox proportional hazards regression model was used for OS analysis, and a Fine and Gray competing risks analysis was performed for LF-free survival and PFS. Univariate analysis (UVA) was performed for the following factors: age at diagnosis, sex, Karnofsky performance score (KPS), histological type, laterality of tumor, clinical and pathological stage, MCR, chemotherapy, RT technique, and RT dose. Factors with a p value of 0.15 or lower were considered candidates for stepwise multivariate analysis (MVA) to evaluate the association of RT technique with each end point. Forward and backward selection procedures were implemented to confirm results. Incidence of significant (grade 2) toxicities were compared between RT techniques by using Fisher's exact test. These results were adjusted for multiple comparisons by the Bonferroni method. Statistical analysis was conducted with SAS software, version 9.4 (SAS Institute Inc. Cary, NC), and the R version 3.1.2 package cmprsk.
Results
Patient Characteristics
We analyzed 209 patients with MPM who met the inclusion criteria. The median age of patients was 64 years (range 34-84), the male-to-female ratio was 4:1, and the median KPS was 80 (range 60-100). Of the 209 patients, 131 (63%) received CONV and 78 (37%) received IMPRINT. All patients treated since March 2005 have received IMPRINT. A total of 85 patients (41%) received chemotherapy (70 patients in the IMPRINT group and 15 in the CONV group). Significant differences between the CONV and IMPRINT groups were noted with respect to the percentage of patients older than 64 years (45% and 65% respectively, p ¼ 0.006), percentage with a KPS higher than 80 (31% and 50% respectively, p ¼ 0.008), percentage with the epithelioid histological type (59% and 86% respectively, p < 0.0001), and percentage with stage pathological stage III and IV (advanced) (49% and 76% respectively, p ¼ 0.0001). Chemotherapy was administered significantly more often in the IMPRINT group (90% versus 11%, p < 0.0001), and IMPRINT was also associated with a higher percentage of patients receiving a total prescription radiation dose higher than 4500 cGy (65% versus 11%, p < 0.0001). Detailed patient characteristics are shown in Table 1 . (Fig. 1) . The 1-and 2-year survival rates were higher for patients receiving IMPRINT (69% and 42% versus 50% and 20% for CONV, respectively).
Factors associated with higher OS on UVA were KPS higher than 80% (versus 80%) (hazard ratio (Table 2) .
Although chemotherapy (versus no chemotherapy) was associated with improved survival in the UVA (HR ¼ 0.63, 95% CI: 0.46-0.86, p ¼ 0.004), it did not enter into the stepwise Cox proportional hazards MVA final model, as it was highly correlated with RT technique. Seventy patients receiving IMPRINT (90%) also underwent chemotherapy, whereas only 15 patients in the CONV cohort (11%) received chemotherapy (p < 0.001 by Fisher's exact test). As IMPRINT entered into the MVA model, chemotherapy did not contribute significantly to the prognosis of OS and thus did not enter into the MVA final model. The results from the MVA final models using stepwise, forward, and backward selection procedures were identical. Further analysis showed that when RT technique was removed as a candidate of the stepwise MVA, KPS higher than 80% (p ¼ 0.009), epithelioid histological type (p ¼ 0.002), MCR (p ¼ 0.02), and chemotherapy (p ¼ 0.02) remained associated with longer OS.
LF
There were 116 cases of LF (56% of all patients); 72 patients died without LF, and 21 patients were censored at last follow-up. The 1-and 2-year cumulative incidences of LF were 42% and 60% for IMPRINT versus 34% and 47% for CONV. There was no significant difference in cumulative incidence of LF between the two groups (p ¼ 0.08 by Gary's test). There were no factors significantly associated with higher rates of local control either in univariate or multivariate analysis.
PFS
Of the 209 patients, 145 (69%) progressed, 48 died without progression of disease, and 16 were censored at last follow-up. The 1-and 2-year cumulative incidences of disease progression were 53% and 72% for IMPRINT and 47% and 69% for CONV. There was no significant difference in cumulative incidence of progression between the groups (p 
Toxicities
Patients undergoing IMPRINT were found to have significantly higher rates of grade 2þ fatigue (47% versus 16%, p < 0.0001) and cough (18% versus 2%, p < 0.0001), whereas those in the CONV cohort showed more cases of grade 2þ esophagitis (23% versus 47%, p ¼ 0.0007) ( Table 3) . After adjustment for multiple comparisons by the Bonferroni method, all p values remained at p less than 0.006. There was no significant difference seen in the rates of grade 2þ radiation pneumonitis (26% in the IMRINT cohort versus 35% in the CONV cohort, p ¼ 0.17), nausea (both 24%, p ¼ 1.0), vomiting (6% versus 8%, p ¼ 1.0), dyspnea (27% versus 24%, p ¼ 0.62), and dermatitis (13% versus 15%, p ¼ 0.69). There were four possibly toxicity-related deaths in the CONV group (two of which were grade 5 radiation pneumonitis) and two in the IMPRINT group (one grade 4 and one grade 5 radiation pneumonitis).
Discussion
Multimodality treatment is commonly the preferred treatment approach for patients with resectable MPM. However, the optimal combination of multimodality therapies remains unclear. At our institution we have a longstanding history of conducting prospective and retrospective studies on the multimodality management of patients with MPM. Here we have presented a complete series of patients treated with multimodality treatment on a lung-sparing surgical backbone of P/D. To our knowledge, it represents the largest series of lung-sparing surgery and adjuvant RT performed by a high-volume institution with significant experience in this complex disease. Patients were treated with adjuvant RT using conventional techniques in the early years and an IMRT technique in the last decade. In these 209 patients with MPM who underwent lung-sparing multimodality treatment, we found promising OS outcomes in patients who received platinum/pemetrexedbased chemotherapy and adjuvant IMPRINT compared with CONV. We also found that a higher KPS and epithelioid histological type were associated with longer OS, which is in line with previously reported results. 22, 23 A few aspects should be considered in addition to the inherent limitations of a retrospective analysis. Our study includes patients treated over 40 years. During this period, many aspects of not only radiation oncology but also medical and surgical oncology have significantly changed. In addition to technical advances in the treatment of MPM, platinum/pemetrexed chemotherapy has, over the past decade, emerged as standard first-line therapy for inoperable MPM 8, 24 and has become an essential part of our multimodality treatment approach. This explains the large discrepancy between the groups from the standpoint of inclusion of chemotherapy in the multimodality treatment (90% in the IMPRINT group and only 11% in the CONV group). Given the observed size of the effect of our modern trimodality treatment approach, we believe that the use of trimodality therapy including both modern platinum/pemetrexed chemotherapy and IMPRINT compared with surgery and CONV RT, radiation therapy; IMPRINT, intensity-modulated pleural radiation therapy.
alone likely prolongs OS. Although the IMPRINT group had some more favorable characteristics (such as higher KPS, more cases of the epithelioid histological type, and more chemotherapy administered), it also had several unfavorable patient characteristics (including older age and more advanced pathological stage) that would likely counteract the favorable characteristics. Our analysis did not identify significant contributors associated with higher incidences of progression or LF on MVA. Although left-sided MPM and female sex were marginally significant on MVA of progression, caution is advised so as not to overinterpret these findings given the 95% CI of 1.00 to 1.41 for left-sided MPM on UVA. Although one could argue that the lack of improved local control within the IMPRINT group means that it is unlikely that radiation has a role in improved survival, it is important to note that patients are followed much more closely and with more precise imaging modalities, such as CT and positron emission tomography/CT imaging, in the era of platinum/pemetrexed chemotherapy and IMPRINT. This development of more accurate imaging has probably increased the likelihood of early recurrence detection and shortened the time for the detection of local and distant failure, which may explain the apparent lack of difference in LF and PFS. In patients with MPM, however, disease progression is so strongly correlated with OS that it is fair to hypothesize that the observed OS benefit is due to improved disease control.
Our toxicity analysis showed higher rates of grade 2þ cough and fatigue in the IMPRINT group but, more significantly, a lower rate of grade 2þ esophagitis compared with in the CONV group. Additionally, although not statistically significant, pneumonitis rates were lower in the IMPRINT group as well. As this is a retrospective study, evaluation of toxicity rates overall remains subject to inaccuracy, especially for patients treated before electronic medical records were available. The higher rates of cough and fatigue may be attributed to the fact that the documentation of toxicities has become more standardized, electronic medical record systems have been established, and toxicities have been more carefully recorded in the past decade. However, the observed significant decrease in grade 2þ esophagitis and numerical albeit not statistically significant decrease in grade 2þ pneumonitis suggests that the use of IMPRINT may lead to less severe side effects. Grading of radiation pneumonitis remains somewhat subjective (e.g., with different thresholds for initiating systemic prednisone for grade 2 pneumonitis). Clinically, we believe that we observe less frequent and less severe radiation pneumonitis with the use of IMPRINT. We may need an even larger patient cohort to show a statistically significant decrease in pneumonitis compared with in the CONV group. In general, however, IMRT has been shown in mesothelioma and multiple other disease sites to be associated with decreased radiation dose to organs at risk, leading to a decrease in toxicities. 14, 25, 26 It is fair to assume that the improved dosimetric control and less radiation to organs at risk with IMPRINT are associated with less toxicity.
To conclude, we have found that IMPRINT in the context of modern chemotherapy and lung-sparing surgery as a part of modern trimodality treatment in MPM is associated with improved outcomes such as higher OS and lower rates of severe toxicity compared with lung-sparing surgery and CONV alone.
